Match Group Inc vs BIO-TECHNE Corp — how do they compare? Match Group Inc trades at $41.48 (market cap $9.53B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Match Group Inc pays the higher dividend (1.93%). Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and BIO-TECHNE Corp for 63 Days on average.
| MTCH | TECH | |
|---|---|---|
Market Cap | $9.53B | $11.36B |
Volume | 3,228,794 | 5,390,331 |
Sector | Media | Health |
52-Week High | $44.40 | $72.61 |
52-Week Low | $28.90 | $43.31 |
Typical Hold Time | 115 Days | 63 Days |
Enterprise Value | $12.49B | $11.39B |
Dividend Yield | 1.93% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $40.86, up 0.59% today, with a bullish technical signal and strong cash flow growth. The company reported a net income margin of 20.17% for 2025, with recent earnings beats in Q4 2025 and Q2 2026. Revenue remains stable at $3.49B, while analyst consensus is a Buy with a $42.29 price target. Positive sentiment is driven by margin expansion and Hinge's growth, though high debt levels and mixed quarterly results present some caution.
The outlook for MTCH is cautiously optimistic, with upside to the consensus target offering ~3.5% potential gain. Strengths include robust profitability, solid cash generation, and product innovation, but risks involve elevated debt, competitive pressures, and reliance on Tinder's turnaround. Investors should weigh strong fundamentals against execution risks in a dynamic dating app market.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Trailing returns across standard periods
Latest headlines on both assets
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →